Comprehensive overview of the recently FDA-approved contraceptive vaginal ring releasing segesterone acetate and ethinylestradiol: A new year-long, patient controlled, reversible birth control method

References

• Bearak J, Popinchalk A, Alkema L, et al. Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: estimates from a Bayesian hierarchical model. Lancet Glob Health. 2018;6(4):e380–e389.
   PubMed Web of Science ®Google Scholar
• Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008–2011. N Engl J Med. 2016;374(9):843–852.
   PubMed Web of Science ®Google Scholar
• Gipson JD, Koenig MA, Hindin MJ. The effects of unintended pregnancy on infant, child, and parental health: a review of the literature. Stud Fam Plann. 2008;39(1):18–38.
   PubMed Web of Science ®Google Scholar
• Kost K, Lindberg L. Pregnancy intentions, maternal behaviors, and infant health: investigating relationships with new measures and propensity score analysis. Demography. 2015;52(1):83–111.
   PubMed Web of Science ®Google Scholar
• Shah PS, Balkhair T, Ohlsson A, et al. Intention to become pregnant and low birth weight and preterm birth: a systematic review. Matern Child Health J. 2011;15(2):205–216.
   PubMed Web of Science ®Google Scholar
• Maguire K, Westhoff C. The state of hormonal contraception today: established and merging noncontraceptive health benefits. Am J Obstet Gynecol. 2011;205(4 Suppl):S4–S8.
   PubMed Web of Science ®Google Scholar
• Nelson AL, Shabaik S, Xandre P, et al. Perceptions of health risks associated with pregnancy compared to oral contraceptive use. Contraception. 2019;100:193–195. S0010–7824(19)30145–3.
   PubMed Web of Science ®Google Scholar
• Westhoff CL, Heartwell S, Edwards S, et al. Oral contraceptive discontinuation: do side effects matter? Am J Obstet Gynecol. 2007;196(4):412.e1–e6.
   Web of Science ®Google Scholar
• Weisberg E, Fraser IS, Lacarra M, et al. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring. Contraception. 1999;59(5):311–318.
   PubMed Web of Science ®Google Scholar
• Archer DF, Merkatz RB, Bahamondes L, et al. Efficacy of the 1-year (13 cycle) segesterone acetate/ethinyl estradiol contraceptive vaginal system: results from Phase 3 trials. Lancet Glob Health. 2019;7(8):e1054–e1064.
   PubMed Web of Science ®Google Scholar
• Fraser IS, Weisberg E, Kumar N, et al. An initial pharmacokinetic study with a metered dose transdermal system for delivery of the progestogen Nestorone as a possible future contraceptive. Contraception. 2007;76(6):432–438.
   PubMed Web of Science ®Google Scholar
• Kumar N, Koide SS, Tsong Y, et al. Nestorone: a progestin with a unique pharmacological profile. Steroids. 2000;65(10–11):629–636.
   PubMed Web of Science ®Google Scholar
• Kumar N, Fagart J, Liere P, et al. Nestorone® as a novel progestin for nonoral contraception: structure-activity relationships and brain metabolism studies. Endocrinology. 2017;158(1):170–182.
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Small M, Kumar N, et al. Nestorone: clinical applications for contraception and HRT. Steroids. 2003;68(10–13):907–913.
   PubMed Web of Science ®Google Scholar
• Haukkamaa M, Laurikka-Routti M, Heikinheimo O, et al. Contraception with subdermal implants releasing the progestin ST-1435: a dose-finding study. Contraception. 1992;45(1):49–55.
   PubMed Web of Science ®Google Scholar
• Lähteenmäki PL, Lähteenmäki P. Concentration-dependent mechanisms of ovulation inhibition by the progestin ST-1435. Fertil Steril. 1985;44(1):20–24.
   PubMed Web of Science ®Google Scholar
• Lähteenmäki P, Weiner E, Lähteenmäki P, et al. Pituitary and ovarian function during contraception with one subcutaneous implant releasing a progestin, ST-1435. Contraception. 1982;25(3):299–306.
   PubMed Web of Science ®Google Scholar
• Archer DF, Thomas MA, Conard J, et al. Impact on hepatic estrogen-sensitive proteins by a 1-year contraceptive vaginal ring delivering nestorone® and ethinyl estradiol. Contraception. 2016;93(1):58–64.
   PubMed Web of Science ®Google Scholar
• Chen S, Kumar N, Mao Z, et al. Therapeutic progestin segesterone acetate promotes neurogenesis: implications for sustaining regeneration in female brain. Menopause. 2018;25(10):1138–1151.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhao L, She H, et al. Clinically relevant progestins regulate neurogenic and neuroprotective responses in vitro and in vivo. Endocrinology. 2010;151(12):5782–5794.
   PubMed Web of Science ®Google Scholar
• Liu A, Margaill I, Zhang S, et al. Progesterone receptors: a key for neuroprotection in experimental stroke. Endocrinology. 2012;153(8):3747–3757.
   PubMed Web of Science ®Google Scholar
• Hussain R, El-Etr M, Gaci O, et al. Progesterone and nestorone facilitate axon remyelination: a role for progesterone receptors. Endocrinology. 2011;152(10):3820–3831.
   PubMed Web of Science ®Google Scholar
• Prasad PV, Bashir M, Sitruk-Ware R, et al. Single-dose pharmacokinetics of nestorone, a potential female-contraceptive. Steroids. 2010;75(3):252–264.
   PubMed Web of Science ®Google Scholar
• Drug approval package: annovera (segesterone acetate and ethinyl estradiol). [cited 2019 Sept 4]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209627Orig1s000TOC.cfm (Labeling)
   Google Scholar
• Creasy G, Brache V, Croxatto H, et al. User controlled long acting reversible contraception: the pharmacokinetic profile of the nesterone/ethinyl estradiol contraceptive vaginal ring (NES/EE-CVR) a 1-year cyclical re-useable vaginal ring. Eur J Contracept Reprod Health Care. 2014;19:S85.
   Google Scholar
• Center for drug evaluation and research. Multi-discipline review application number 209627 Orig1s000. 2018 Jun 29. [cited 2019 Sept 4]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209627Orig1s000MultidisciplineR.pdf.
   Google Scholar
• McCoy CF, Apperley DC, Variano B, et al. Solid state (13)C NMR spectroscopy provides direct evidence for reaction between ethinyl estradiol and a silicone elastomer vaginal ring drug delivery system. Int J Pharm. 2018;548(1):689–697.
   PubMedGoogle Scholar
• Noé G, Salvatierra A, Heikinheimo O, et al. Pharmacokinetics and bioavailability of SA 1435 administered by different routes. Contraception. 1993;48(6):548–556.
   PubMed Web of Science ®Google Scholar
• Fraser IS, Weisberg E, Brache V, et al. Serum nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen. Contraception. 2005;72(1):40–45.
   PubMed Web of Science ®Google Scholar
• Paton DM. Contraceptive vaginal ring containing segesterone acetate and ethinyl estradiol: long-acting, patient-controlled, procedure-free, reversible prescription birth control. Drugs Today (Barc). 2019;55(7):449–457.
   PubMed Web of Science ®Google Scholar
• Sivin I, Mishell DR Jr, Alvarez F, et al. Contraceptive vaginal rings releasing nestorone and ethinylestradiol: a 1-year dose-finding trial. Contraception. 2005;71(2):122–129.
   PubMed Web of Science ®Google Scholar
• Simmons KB, Kumar N, Plagianos M, et al. Effects of concurrent vaginal miconazole treatment on the absorption and exposure of nestorone® (segesterone acetate) and ethinyl estradiol delivered from a contraceptive vaginal ring: a randomized, crossover drug-drug interaction study. Contraception. 2018;97(3):270–276.
   PubMed Web of Science ®Google Scholar
• U.S. Medical Eligibility Criteria for Contraceptive Use, 2016 [cited 2019 Sept 4]. Available from: https://www.cdc.gov/mmwr/volumes/65/rr/rr6503a1.htm?s_cid=rr6503a1_w.
   Google Scholar
• WHO Medical egibility criteria for contraceptive use. [Last accessed 2019 Sept 4]. Available from: https://www.who.int/reproductivehealth/publications/family_planning/MEC-5/en/.
   Google Scholar
• Brache V, Massai R, Mishell DR, et al. Ovarian function during use of nestorone(R) subdermal implants. Contraception. 2000;61(3):199–204.
   PubMed Web of Science ®Google Scholar
• Merkatz RB, Plagianos M, Hoskin E, et al. Acceptability of the nestorone®/ethinyl estradiol contraceptive vaginal ring: development of a model; implications for introduction. Contraception. 2014;90(5):514–521.
   PubMed Web of Science ®Google Scholar
• Nelson AL, Vieira CS, Fraser I, et al. Bleeding patterns with a 1-year, segesterone acetate/ethinyl estradiol contraceptive vaginal system. Poster Presentation ACOG ACM; 2019 April 05; Nashville, TN.
   Google Scholar
• Vieira CS, Fraser IS, Plagianos MG, et al. Bleeding profile associated with 1-year use of the segesterone acetate/ethinyl estradiol contraceptive vaginal system: pooled analysis from Phase 3 trials. Contraception. 2019. pii: S0010-7824(19)30382-8. [Epub ahead of print].
   Google Scholar
• Archer DF, Barnhart KT, Creinin MD, et al. Endometrial safety with a 1-year Segesterone acetate/ethinyl estradiol contraceptive vatinal system. Poster presented at ACOG ACM; 2019 May 4; Nashville, TN; 2019.
   Google Scholar
• Gemzell-Danielsson K, Sitruk-Ware R, Creinin MD, et al. Segesterone acetate/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation. Contraception. 2019;99(6):323–328.
   PubMed Web of Science ®Google Scholar
• Thomas MA, Gemzell-Danielsson K, Creinin MD, et al. Segesterone acetate/ethinyl estradiol 1-year contraceptive vaginal system safety evaluation. Poster presented at ACOG ACM; 2019 May 4; Nashville, TN.
   Google Scholar
• Huang Y, Merkatz RB, Hillier SL, et al. Effects of a one year reusable contraceptive vaginal ring on vaginal microflora and the risk of vaginal infection: an open-label prospective evaluation. PLoS One. 2015;10(8):e0134460.
   PubMed Web of Science ®Google Scholar
• Ballagh SA. Vaginal rings for menopausal symptom relief. Drugs Aging. 2004;21(12):757–766.
   PubMed Web of Science ®Google Scholar
• Trussell J, Portman D. The creeping Pearl: why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills? Contraception. 2013;88(5):604–610.
   PubMed Web of Science ®Google Scholar
• Westhoff CL, Torgal AT, Mayeda ER, et al. Predictors of noncompliance in an oral contraceptive clinical trial. Contraception. 2012;85(5):465–469.
   PubMed Web of Science ®Google Scholar
• Gerlinger C, Trussell J, Mellinger U, et al. Different Pearl Indices in studies of hormonal contraceptives in the United States: impact of study population. Contraception. 2014;90(2):142–146.
   PubMed Web of Science ®Google Scholar
• Jensen JT, Edelman AB, Chen BA, et al. Continuous dosing of a novel contraceptive vaginal ring releasing nestorone® and estradiol: pharmacokinetics from a dose-finding study. Contraception. 2018;97(5):422–427.
   PubMed Web of Science ®Google Scholar
• Brache V, Merkatz R, Kumar N, et al. A dose-finding, cross-over study to evaluate the effect of a nestorone®/estradiol transdermal gel delivery on ovulation suppression in normal ovulating women. Contraception. 2015;92(4):289–297.
   PubMed Web of Science ®Google Scholar
• Monteiro I, Guazzelli CF, Bahamondes L. Advances in contraceptive vaginal rings: what does the future hold? Expert Opin Pharmacother. 2018;19(15):1685–1691.
   PubMed Web of Science ®Google Scholar
• Brache V, Sitruk-Ware R, Williams A, et al. Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women. Contraception. 2012;85(5):480–488.
   PubMed Web of Science ®Google Scholar
• Fox MC, Klipping C, Nguyen AM, et al. A phase 2b multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of vaginal rings containing nomegestrol acetate or etonogestrel and 17β-estradiol in the treatment of women with primary dysmenorrhea. Contraception. 2019;99(2):125–130.
   PubMed Web of Science ®Google Scholar